M344: Potent HDAC Inhibitor (IC50 100 nM) for Cancer & HIV-1 Research

Executive Summary: M344 is a cell-permeable HDAC inhibitor with an IC50 of 100 nM, exhibiting strong anticancer activity in neuroblastoma, breast cancer, and medulloblastoma cell lines (Brumfield et al., 2025). It induces G0/G1 cell cycle arrest and caspase-mediated apoptosis, independent of p53 status. In vivo, metronomic dosing of M344 suppresses tumor growth and extends survival in neuroblastoma models. M344 also enhances the efficacy of chemotherapeutics, such as topotecan and cyclophosphamide, by improving tolerability and reducing tumor rebound. The compound has demonstrated unique potential for HIV-1 latency reversal by activating latent viral gene expression (APExBIO).

Biological Rationale

Histone deacetylase (HDAC) enzymes regulate chromatin structure and gene expression by removing acetyl groups from histone proteins. In many cancers, increased HDAC activity is correlated with histone hypoacetylation and repression of tumor suppressor genes. This leads to enhanced cell proliferation, impaired apoptosis, and increased tumor invasiveness (Brumfield et al., 2025). Targeting HDACs with selective inhibitors such as M344 can restore acetylation levels, reactivate silenced genes, and induce differentiation or apoptosis in tumor cells. HDAC inhibitors are increasingly explored for their ability to modulate gene expression, alter tumor phenotypes, and potentiate other therapeutic modalities. Clinical and preclinical studies have shown that HDAC inhibition is particularly effective in aggressive tumors with high HDAC expression, such as neuroblastoma (Brumfield et al., 2025).

Mechanism of Action of M344

M344 is a small-molecule, cell-permeable HDAC inhibitor. It inhibits the enzymatic activity of HDACs with an in vitro IC50 of 100 nM (APExBIO). By preventing HDAC-mediated deacetylation, M344 increases acetylation of histone tails, leading to chromatin relaxation and transcriptional activation. This epigenetic modulation upregulates genes involved in cell cycle arrest (e.g., p21), apoptosis (e.g., Puma), and differentiation. Importantly, M344 can induce pro-apoptotic factors through p53-independent pathways, expanding its utility to tumors with diverse genetic backgrounds (Brumfield et al., 2025). M344 also modulates the NF-κB transcription factor pathway, further influencing gene expression relevant to cancer survival and immune evasion. In HIV-1 research, M344 activates viral LTR gene expression, offering a strategy for latency reversal therapies.

Evidence & Benchmarks

• M344 inhibits HDAC activity in vitro with an IC50 of 100 nM (ethanol/DMSO, 25°C, 30 min) (APExBIO).
• In MCF-7 breast cancer, D341 MED medulloblastoma, and CH-LA 90 neuroblastoma cell lines, M344 shows GI50 values ranging from 0.63–0.65 μM (72 h, RPMI-1640, 5% CO₂, 37°C) (APExBIO).
• In neuroblastoma, M344 increases histone acetylation and induces G0/G1 cell cycle arrest and caspase-dependent apoptosis (Brumfield et al., Figure 4; https://doi.org/10.3390/ijms26178494).
• Metronomic dosing of M344 in vivo suppresses neuroblastoma tumor growth and extends animal survival (Brumfield et al., Figure 7; https://doi.org/10.3390/ijms26178494).
• M344 co-administration with topotecan or cyclophosphamide reduces toxicity and tumor rebound, enhancing therapeutic outcomes (Brumfield et al., Table 2; https://doi.org/10.3390/ijms26178494).
• M344 induces HIV-1 LTR gene expression in latency models, supporting its use in anti-latency HIV-1 research (APExBIO; https://www.apexbt.com/m344.html).

This article extends the mechanistic detail provided by M344: A Potent HDAC Inhibitor Advancing Cancer & HIV-1 Research by including new quantitative in vivo benchmarks and workflow integration guidance. For additional mechanistic perspectives, see M344: Mechanistic Insights and Translational Advances in Cancer and HIV-1, which is complemented here with a focus on practical experimental conditions and comparative efficacy.

Applications, Limits & Misconceptions

M344 is broadly applicable for research in cancer epigenetics, apoptosis assays, and HIV-1 latency models. It is particularly valuable for:

• Cell differentiation induction in tumor models.
• Breast cancer, medulloblastoma, and neuroblastoma cell proliferation inhibition.
• Potentiating responses to radiation and chemotherapeutic agents in vitro and in vivo.
• Studying NF-κB signaling and gene expression modulation.
• HIV-1 latency reversal strategies.

Common Pitfalls or Misconceptions

• M344 is not water soluble; improper solvent selection impairs activity (prefer DMSO or ethanol with ultrasound; see APExBIO).
• M344 is not suitable for clinical or diagnostic use; for research use only.
• Long-term storage in solution reduces potency; always prepare fresh aliquots for critical assays.
• Its efficacy in non-epigenetic disease models is unproven and not established.
• Not all cell types are equally sensitive—optimization of dose and duration is required for each model system.

Workflow Integration & Parameters

M344 (SKU: A4105) is supplied as a solid by APExBIO and should be stored at -20°C. Dissolve in DMSO (≥14.75 mg/mL) or ethanol (≥12.88 mg/mL with ultrasonic treatment). Working concentrations typically range from 1 μM to 100 μM, with treatment durations from 1 to 7 days depending on the assay and cell type (APExBIO). Avoid repeated freeze-thaw cycles and do not store working solutions for extended periods. For apoptosis and cell cycle assays, use validated protocols on cell lines such as MCF-7, D341 MED, or CH-LA 90. For HIV-1 latency studies, M344 can be combined with reporter assays for LTR activation. Always handle with appropriate laboratory safety measures. For detailed protocols and application notes, see the M344 product page. For strategic guidance on translational research, compare with M344: Advanced Strategies for HDAC Inhibition in Neuroblastoma, which provides in-depth discussion of pathway modulation—this article emphasizes experimental conditions and validated endpoints.

Conclusion & Outlook

M344 is a highly potent and versatile HDAC inhibitor for research in cancer biology and HIV-1 latency. Its nanomolar IC50, robust apoptosis induction, and proven in vivo efficacy support its continued use in preclinical models. Ongoing studies may further delineate its clinical potential and inform combination therapies. For the latest specifications and ordering information, visit the APExBIO product page.